Prostate Cancer Precision Therapy Dream Team - Stand Up to Cancer
Help save a life

This holiday season, Mastercard is standing with us in the fight to end cancer as we know it. From now until December 31st, 2018, if you use a Mastercard to donate to Stand Up To Cancer, Mastercard will TRIPLE your gift, up to $300,000!

That’s triple the impact to support groundbreaking cancer research that will help save lives now!

$25 = $75
$50 = $150
$100 = $300
$250 = $750
GIVE FOR LIFE
For every $1 donated through StandUpToCancer.org with a Mastercard, Mastercard will donate $2, up to $300,000. Offer starts 12/14/18 at 12:01am ET and ends 12/31/18 at 11:59pm ET, or at the $300,000 max, whichever comes first.

Dream Teams

Research  >  Research Portfolio  >  Dream Teams  >  Prostate Cancer Precision Therapy Dream Team

SU2C−Prostate Cancer Foundation Prostate Dream Team:
Precision Therapy of Advanced Prostate Cancer

Grant Term: August 2012−July 2016

Recent studies have demonstrated tremendous diversity in the genetic makeup of metastatic castration-resistant prostate cancer (mCRPC). The SU2C−Prostate Cancer Foundation (PCF) Prostate Dream Team is sequencing patient DNA and systematically comparing it with patient response to therapies. The aim is to identify biomarkers and predictors that will help physicians determine the best treatments for patients based on their molecular profiles.

ABOUT THIS TEAM’S RESEARCH

The SU2C−PCF Prostate Dream Team hypothesizes that the molecular qualities of a patient’s castration-resistant prostate cancer can guide the doctor in choosing a treatment that is best tailored to the patient. To advance this precision therapy, researchers have implemented a multicenter study that systematically evaluates patients enrolling in four clinical trials for CRPC, identified predictors of response, and identified predictors of resistance.

MEET THE TEAM

The top scientists and researchers on the SU2C−PCF Prostate Dream Team come from a variety of backgrounds and disciplines, which leads them to great insights upon collaboration. Learn more about the SU2C−PCF Prostate Dream Team.

Team Members

Arul M. Chinnaiyan, MD, PhD
University of Michigan
Team Leader

Charles L. Sawyers, MD
Memorial Sloan Kettering Cancer Center
Co-leader

Johann S. de Bono, MD, PhD
Institute of Cancer Research, Royal Marsden NHS Foundation Trust
Principal Investigator

Levi A. Garraway, MD, PhD
Dana-Farber Cancer Institute
Principal Investigator

Philip W. Kantoff, MD
Memorial Sloan Kettering Cancer Center
Principal Investigator

Peter S. Nelson, MD
Fred Hutchinson Cancer Research Center
Principal Investigator

Mark A. Rubin, MD
Weill Cornell Medicine
Principal Investigator

Woods Brown
University of Michigan
Advocate

Thomas A. Farrington
Advocate

Grant Gregory
Memorial Sloan Kettering Cancer Center
Advocate

James Kiefert
Us TOO! International, Inc.
Advocate

Stan Klein
Longwood Medical Area Prostate Cancer Support Group
Advocate

Ian Liston
Advocate

Douglas Pergament
University of Michigan
Advocate

Karen Giles
University of Michigan
Project Manager

“Utilizing this Dream Team grant, we will be able to bring together great scientists and clinicians from around the world to join in the fight against metastatic prostate cancer. We hope this unique model of research will lead to patient benefit in the short term.”

Arul M. Chinnaiyan, MD, PhD
University of Michigan

TEAM PROGRESS UPDATES

Stand Up To Cancer’s research projects are designed to foster collaborative, swift translational research. The hallmarks of these efforts include rigorous application and selection procedures, sufficient funding to allow scientists to focus on the objectives of the grant, and reviews by senior scientists every six months. These reviews help the investigators capitalize on the latest findings, address potential roadblocks, and collaboratively evolve as the science requires. Please click below to see summaries of research results for the SU2C–PCF Prostate Dream Team.

TEAM PROGRESS UPDATES

PUBLICATIONS

Inherited DNA Repair Gene Mutations in Men with Metastatic Prostate Cancer
Chinnaiyan A, Garraway L, Sawyers C, de Bono J, et al. (2016)
New England Journal of Medicine 375(5):443-53.
Integrative Clinical Genomics of Advanced Prostate Cancer.
de Bono JS, Garraway LA, Sawyers CL, Chinnaiyan AM, et al. (2015)
Cell 161(5):1215-28.

CLINICAL TRIALS REFERRALS

Cancer clinical trials allow researchers to study innovative and potentially life-saving new treatments. The goal is to find treatments that are better than what’s currently available; in fact, the therapies offered to today’s cancer patients were almost all studied and made possible by people participating in clinical trials. But many cancer clinical trials aren’t completed because not enough people take part.

At StandUpToCancer.org/ClinicalTrials, you’ll find information and answers to common questions about clinical trials. Learn more and talk to your doctor to see if a clinical trial may be the best choice for you.

You can also connect with EmergingMed, a free and confidential clinical trial matching service that provides access to a vast database to help you identify the clinical trials that might be right for you or your loved one.

LEARN MORE